Literature DB >> 1710739

Pathophysiology of hyperlipidemia in diabetes mellitus.

S L Abbate1, J D Brunzell.   

Abstract

Many lipoprotein abnormalities are seen in the untreated, hyperglycemic diabetic patient. The non-insulin-dependent diabetic (NIDDM) patient with mild fasting hyperglycemia commonly has mild hypertriglyceridemia due to overproduction of TG-rich lipoproteins in the liver, associated with decreased high-density lipoprotein (HDL) cholesterol levels. The more hyperglycemic untreated NIDDM and insulin-dependent diabetic (IDDM) patient have mild to moderate hypertriglyceridemia due to decreased adipose tissue and muscle lipoprotein lipase, (LPL) activity. These patients also have decreased HDL cholesterol levels associated with defective LPL catabolism of TG-rich lipoproteins. Treatment of diabetes with oral sulfonylureas or insulin corrects most of the hypertriglyceridemia and some of the decrease in HDL cholesterol. The abnormality in adipose tissue LPL activity corrects slowly over several months of therapy. The treated IDDM patient often has normal lipoprotein levels. The treated NIDDM patient may continue to have mild hypertriglyceridemia, increased intermediate-density lipoprotein levels, small dense low-density lipoproteins (LDL) with increased apoprotein B, and decreased HDL cholesterol levels. The central, abdominal distribution of adipose tissue in IDDM is associated with insulin resistance, hypertension, and the above lipoprotein abnormalities. Improvement in glucose control, in the absence of weight gain, leads to lower triglyceride and higher HDL cholesterol levels. In addition, the diabetic patient is prone to develop other defects that, in themselves, lead to hyperlipidemia, such as proteinuria, hypothyroidism, and hypertension, treated with thiazide diuretics and beta-adrenergic-blocking agents. When a diabetic patient independently inherits a common familial form of hypertriglyceridemia, he might develop the severe hypertriglyceridemia of the chylomicronemia syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1710739

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  15 in total

1.  Neonatal diabetes with hyperchylomicronemia.

Authors:  Zehra Aycan; Merih Berberoğlu; Gönül Ocal; Nilgün Altundas; Pelin Adiyaman; Olcay Evliyaoğlu
Journal:  Indian J Pediatr       Date:  2002-12       Impact factor: 1.967

2.  Antihypertriglyceridemia and anti-inflammatory activities of monascus-fermented dioscorea in streptozotocin-induced diabetic rats.

Authors:  Yeu-Ching Shi; Jiunn-Wang Liao; Tzu-Ming Pan
Journal:  Exp Diabetes Res       Date:  2011-05-11

3.  Antihyperglycemic and antihyperlipidemic activity of plectranthus amboinicus on normal and alloxan-induced diabetic rats.

Authors:  A H M Viswanathaswamy; B C Koti; Aparna Gore; A H M Thippeswamy; R V Kulkarni
Journal:  Indian J Pharm Sci       Date:  2011-03       Impact factor: 0.975

4.  Gene therapy for lipid disorders.

Authors:  Daniel J Rader
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

5.  Antidiabetic effects of Brucea javanica seeds in type 2 diabetic rats.

Authors:  Abdulwali Ablat; Mohammed Farouq Halabi; Jamaludin Mohamad; Muhammad Hafiz Husna Hasnan; Hazrina Hazni; Ser-Huy Teh; Jamil A Shilpi; Zulqarnain Mohamed; Khalijah Awang
Journal:  BMC Complement Altern Med       Date:  2017-02-06       Impact factor: 3.659

6.  Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3.

Authors:  Yu-Hsuan Lin; Jiun-Chi Huang; Pei-Yu Wu; Szu-Chia Chen; Yi-Wen Chiu; Jer-Ming Chang; Hung-Chun Chen
Journal:  Oncotarget       Date:  2017-12-14

7.  Leu452His mutation in lipoprotein lipase gene transfer associated with hypertriglyceridemia in mice in vivo.

Authors:  Kaiyue Sun; Wei Yang; Yanna Huang; Yizhen Wang; Lan Xiang; Jianhua Qi
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

8.  The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital.

Authors:  Amit Kumar Dixit; Ranjit Dey; Aela Suresh; Siddhartha Chaudhuri; Ashok Kumar Panda; Achintya Mitra; Jayram Hazra
Journal:  J Diabetes Metab Disord       Date:  2014-05-22

9.  Antidiabetic and Antilipidemic Effect of Musa balbisiana Root Extract: A Potent Agent for Glucose Homeostasis in Streptozotocin-Induced Diabetic Rat.

Authors:  Himadri Kalita; Dulal C Boruah; Meetali Deori; Ankita Hazarika; Rahul Sarma; Sima Kumari; Raghuram Kandimalla; Jibon Kotoky; Rajlakshmi Devi
Journal:  Front Pharmacol       Date:  2016-05-02       Impact factor: 5.810

Review 10.  Environmental Risk Factors for Congenital Heart Disease.

Authors:  Jacinta Isabelle Kalisch-Smith; Nikita Ved; Duncan Burnaby Sparrow
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.